$VPHM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in VIROPHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in VIROPHARMA INC. Get notifications about new insider transactions in VIROPHARMA INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 11 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Option Exercise | M | 1.84 | 90,000 | 165,600 | 30,000 | |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 2,134 | 106,273 | 154,058 | 156.2 K to 154.1 K (-1.37 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 19.73 | 5,068 | 99,992 | 156,192 | 151.1 K to 156.2 K (+3.35 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 2,196 | 109,361 | 151,124 | 153.3 K to 151.1 K (-1.43 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 15.24 | 6,561 | 99,990 | 153,320 | 146.8 K to 153.3 K (+4.47 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 2,231 | 111,104 | 146,759 | 149 K to 146.8 K (-1.50 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 13.50 | 7,407 | 99,995 | 148,990 | 141.6 K to 149 K (+5.23 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 1,175 | 58,515 | 141,583 | 142.8 K to 141.6 K (-0.82 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 9.99 | 5,025 | 50,200 | 142,758 | 137.7 K to 142.8 K (+3.65 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 1,166 | 58,067 | 137,733 | 138.9 K to 137.7 K (-0.84 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 9.96 | 5,001 | 49,810 | 138,899 | 133.9 K to 138.9 K (+3.73 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 2,773 | 138,095 | 133,898 | 136.7 K to 133.9 K (-2.03 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 8.86 | 13,080 | 115,889 | 136,671 | 123.6 K to 136.7 K (+10.58 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 1,551 | 77,240 | 123,591 | 125.1 K to 123.6 K (-1.24 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 5.91 | 10,000 | 59,100 | 125,142 | 115.1 K to 125.1 K (+8.68 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Payment of Exercise | F | 49.80 | 6,914 | 344,317 | 115,142 | 122.1 K to 115.1 K (-5.66 %) |
Jan 10 2014 | VPHM | VIROPHARMA INC | Broom Colin MD | VP & Chief Scientif ... | Buy | M | 1.84 | 90,000 | 165,600 | 122,056 | 32.1 K to 122.1 K (+280.76 %) |
Jan 08 2014 | VPHM | VIROPHARMA INC | BROOKE PAUL A | Director | Option Exercise | M | 3.42 | 10,000 | 34,200 | 0 | |
Jan 08 2014 | VPHM | VIROPHARMA INC | BROOKE PAUL A | Director | Payment of Exercise | F | 49.89 | 686 | 34,225 | 128,314 | 129 K to 128.3 K (-0.53 %) |
Jan 08 2014 | VPHM | VIROPHARMA INC | BROOKE PAUL A | Director | Buy | M | 3.42 | 10,000 | 34,200 | 129,000 | 119 K to 129 K (+8.40 %) |
Jan 07 2014 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 3.55 | 40,309 | 143,097 | 0 | |
Jan 07 2014 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 3.55 | 40,309 | 143,097 | 403,155 | 362.8 K to 403.2 K (+11.11 %) |
Jan 03 2014 | VPHM | VIROPHARMA INC | McHugh Julie | Director | Grant | A | 0.00 | 2,083 | 0 | 8,666 | 6.6 K to 8.7 K (+31.64 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Option Exercise | M | 5.91 | 4,675 | 27,629 | 5,325 | |
Dec 31 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Payment of Exercise | F | 49.86 | 725 | 36,149 | 36,528 | 37.3 K to 36.5 K (-1.95 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Buy | M | 5.91 | 4,675 | 27,629 | 37,253 | 32.6 K to 37.3 K (+14.35 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Option Exercise | M | 5.91 | 4,540 | 26,831 | 5,460 | |
Dec 31 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Payment of Exercise | F | 49.86 | 704 | 35,101 | 64,722 | 65.4 K to 64.7 K (-1.08 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Buy | M | 5.91 | 4,540 | 26,831 | 65,426 | 60.9 K to 65.4 K (+7.46 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Option Exercise | M | 5.91 | 11,500 | 67,965 | 1,000 | |
Dec 31 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Payment of Exercise | F | 49.86 | 1,809 | 90,197 | 138,350 | 140.2 K to 138.4 K (-1.29 %) |
Dec 31 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Buy | M | 5.91 | 11,500 | 67,965 | 140,159 | 128.7 K to 140.2 K (+8.94 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Option Exercise | M | 8.86 | 33,206 | 294,205 | 26,794 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Option Exercise | M | 5.91 | 10,000 | 59,100 | 10,000 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Option Exercise | M | 9.96 | 6,705 | 66,782 | 13,295 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Payment of Exercise | F | 49.74 | 17,411 | 866,023 | 32,578 | 50 K to 32.6 K (-34.83 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Buy | M | 8.86 | 33,206 | 294,205 | 49,989 | 16.8 K to 50 K (+197.85 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Payment of Exercise | F | 49.74 | 3,964 | 197,169 | 16,783 | 20.7 K to 16.8 K (-19.11 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Buy | M | 5.91 | 10,000 | 59,100 | 20,747 | 10.7 K to 20.7 K (+93.05 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Payment of Exercise | F | 49.74 | 3,813 | 189,659 | 10,747 | 14.6 K to 10.7 K (-26.19 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Pietrusko Robert | VP, Regulatory & Qu ... | Buy | M | 9.96 | 6,705 | 66,782 | 14,560 | 7.9 K to 14.6 K (+85.36 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Option Exercise | M | 8.86 | 23,206 | 205,605 | 26,794 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Option Exercise | M | 5.91 | 10,000 | 59,100 | 10,000 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Option Exercise | M | 11.96 | 15,800 | 188,968 | 24,117 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Payment of Exercise | F | 49.74 | 11,835 | 588,673 | 60,886 | 72.7 K to 60.9 K (-16.27 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Buy | M | 8.86 | 23,206 | 205,605 | 72,721 | 49.5 K to 72.7 K (+46.87 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Payment of Exercise | F | 49.74 | 3,964 | 197,169 | 49,515 | 53.5 K to 49.5 K (-7.41 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Buy | M | 5.91 | 10,000 | 59,100 | 53,479 | 43.5 K to 53.5 K (+23.00 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Payment of Exercise | F | 49.74 | 9,330 | 464,074 | 43,479 | 52.8 K to 43.5 K (-17.67 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Rowland Charles A Jr | VP, Chief Financial ... | Buy | M | 11.96 | 15,800 | 188,968 | 52,809 | 37 K to 52.8 K (+42.69 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | DOUGHERTY MICHAEL R | Director | Option Exercise | M | 3.42 | 10,000 | 34,200 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | DOUGHERTY MICHAEL R | Director | Payment of Exercise | F | 49.74 | 688 | 34,221 | 20,812 | 21.5 K to 20.8 K (-3.20 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | DOUGHERTY MICHAEL R | Director | Buy | M | 3.42 | 10,000 | 34,200 | 21,500 | 11.5 K to 21.5 K (+86.96 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Option Exercise | M | 8.86 | 83,284 | 737,896 | 41,716 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Option Exercise | M | 5.91 | 37,500 | 221,625 | 12,500 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Payment of Exercise | F | 49.74 | 46,554 | 2,315,596 | 128,659 | 175.2 K to 128.7 K (-26.57 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Buy | M | 8.86 | 83,284 | 737,896 | 175,213 | 91.9 K to 175.2 K (+90.60 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Payment of Exercise | F | 49.74 | 17,529 | 871,892 | 91,929 | 109.5 K to 91.9 K (-16.01 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | SOLAND DANIEL B | VP, Chief Operating ... | Buy | M | 5.91 | 37,500 | 221,625 | 109,458 | 72 K to 109.5 K (+52.11 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 11.31 | 52,500 | 593,775 | 17,500 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 8.86 | 135,000 | 1,196,100 | 45,000 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 5.91 | 1,310 | 7,742 | 12,690 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 13.50 | 76,593 | 1,034,006 | 7,407 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 9.99 | 111,222 | 1,111,108 | 3,778 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 9.96 | 18,749 | 186,740 | 6,251 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 13.97 | 50,000 | 698,500 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 15.24 | 48,439 | 738,210 | 6,561 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 8.71 | 60,000 | 522,600 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Option Exercise | M | 7.05 | 32,497 | 229,104 | 7,503 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 30,733 | 1,528,659 | 362,846 | 393.6 K to 362.8 K (-7.81 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 11.31 | 52,500 | 593,775 | 393,579 | 341.1 K to 393.6 K (+15.39 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 75,462 | 3,753,480 | 341,079 | 416.5 K to 341.1 K (-18.12 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 8.86 | 135,000 | 1,196,100 | 416,541 | 281.5 K to 416.5 K (+47.95 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 522 | 25,964 | 281,541 | 282.1 K to 281.5 K (-0.19 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 5.91 | 1,310 | 7,742 | 282,063 | 280.8 K to 282.1 K (+0.47 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 46,649 | 2,320,321 | 280,753 | 327.4 K to 280.8 K (-14.25 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 13.50 | 76,593 | 1,034,006 | 327,402 | 250.8 K to 327.4 K (+30.54 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 63,528 | 3,159,883 | 250,809 | 314.3 K to 250.8 K (-20.21 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 9.99 | 111,222 | 1,111,108 | 314,337 | 203.1 K to 314.3 K (+54.76 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 10,704 | 532,417 | 203,115 | 213.8 K to 203.1 K (-5.01 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 9.96 | 18,749 | 186,740 | 213,819 | 195.1 K to 213.8 K (+9.61 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 30,706 | 1,527,316 | 195,070 | 225.8 K to 195.1 K (-13.60 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 13.97 | 50,000 | 698,500 | 225,776 | 175.8 K to 225.8 K (+28.45 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 30,410 | 1,512,593 | 175,776 | 206.2 K to 175.8 K (-14.75 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 15.24 | 48,439 | 738,210 | 206,186 | 157.7 K to 206.2 K (+30.71 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 33,441 | 1,663,355 | 157,747 | 191.2 K to 157.7 K (-17.49 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 8.71 | 60,000 | 522,600 | 191,188 | 131.2 K to 191.2 K (+45.74 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Payment of Exercise | F | 49.74 | 15,655 | 778,680 | 131,188 | 146.8 K to 131.2 K (-10.66 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | MILANO VINCENT | President and CEO | Buy | M | 7.05 | 32,497 | 229,104 | 146,843 | 114.3 K to 146.8 K (+28.42 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 13.97 | 7,500 | 104,775 | 2,500 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 20.07 | 8,930 | 179,225 | 26,793 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 17.98 | 20,130 | 361,937 | 20,131 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 17.84 | 19,856 | 354,231 | 20,405 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 11.31 | 6,250 | 70,688 | 6,250 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 8.86 | 3,164 | 28,033 | 9,336 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 5.91 | 4,000 | 23,640 | 4,000 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 13.50 | 6,000 | 81,000 | 6,000 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 9.99 | 9,298 | 92,887 | 6,952 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 9.96 | 6,000 | 59,760 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 15.24 | 5,048 | 76,932 | 4,452 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Option Exercise | M | 8.71 | 4,051 | 35,284 | 6,949 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 4,591 | 228,356 | 40,983 | 45.6 K to 41 K (-10.07 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 13.97 | 7,500 | 104,775 | 45,574 | 38.1 K to 45.6 K (+19.70 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 6,058 | 301,325 | 38,074 | 44.1 K to 38.1 K (-13.73 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 20.07 | 8,930 | 179,225 | 44,132 | 35.2 K to 44.1 K (+25.37 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 13,201 | 656,618 | 35,202 | 48.4 K to 35.2 K (-27.27 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 17.98 | 20,130 | 361,937 | 48,403 | 28.3 K to 48.4 K (+71.20 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 12,992 | 646,222 | 28,273 | 41.3 K to 28.3 K (-31.48 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 17.84 | 19,856 | 354,231 | 41,265 | 21.4 K to 41.3 K (+92.75 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 3,647 | 181,402 | 21,409 | 25.1 K to 21.4 K (-14.56 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 11.31 | 6,250 | 70,688 | 25,056 | 18.8 K to 25.1 K (+33.23 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 1,383 | 68,790 | 18,806 | 20.2 K to 18.8 K (-6.85 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 8.86 | 3,164 | 28,033 | 20,189 | 17 K to 20.2 K (+18.58 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 1,585 | 78,838 | 17,025 | 18.6 K to 17 K (-8.52 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 5.91 | 4,000 | 23,640 | 18,610 | 14.6 K to 18.6 K (+27.38 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 3,643 | 181,203 | 14,610 | 18.3 K to 14.6 K (-19.96 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 13.50 | 6,000 | 81,000 | 18,253 | 12.3 K to 18.3 K (+48.97 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 4,961 | 246,760 | 12,253 | 17.2 K to 12.3 K (-28.82 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 9.99 | 9,298 | 92,887 | 17,214 | 7.9 K to 17.2 K (+117.46 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 2,713 | 134,945 | 7,916 | 10.6 K to 7.9 K (-25.52 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 9.96 | 6,000 | 59,760 | 10,629 | 4.6 K to 10.6 K (+129.62 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 3,161 | 157,228 | 4,629 | 7.8 K to 4.6 K (-40.58 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 15.24 | 5,048 | 76,932 | 7,790 | 2.7 K to 7.8 K (+184.10 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Payment of Exercise | F | 49.74 | 1,761 | 87,592 | 2,742 | 4.5 K to 2.7 K (-39.11 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Wolf John Peter III | VP, General Counsel | Buy | M | 8.71 | 4,051 | 35,284 | 4,503 | 452 to 4.5 K (+896.24 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 17.98 | 14,000 | 251,720 | 26,261 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 17.84 | 19,398 | 346,060 | 20,863 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 11.31 | 4,657 | 52,671 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 8.86 | 3,000 | 26,580 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 5.91 | 4,000 | 23,640 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 13.50 | 6,000 | 81,000 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 9.99 | 10,012 | 100,020 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 9.96 | 3,750 | 37,350 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 13.97 | 9,000 | 125,730 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 15.24 | 7,620 | 116,129 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Option Exercise | M | 8.71 | 7,535 | 65,630 | 0 | |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 9,198 | 457,509 | 37,227 | 46.4 K to 37.2 K (-19.81 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 17.98 | 14,000 | 251,720 | 46,425 | 32.4 K to 46.4 K (+43.18 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 12,714 | 632,394 | 32,425 | 45.1 K to 32.4 K (-28.17 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 17.84 | 19,398 | 346,060 | 45,139 | 25.7 K to 45.1 K (+75.36 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 2,724 | 135,492 | 25,741 | 28.5 K to 25.7 K (-9.57 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 11.31 | 4,657 | 52,671 | 28,465 | 23.8 K to 28.5 K (+19.56 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 1,316 | 65,458 | 23,808 | 25.1 K to 23.8 K (-5.24 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 8.86 | 3,000 | 26,580 | 25,124 | 22.1 K to 25.1 K (+13.56 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 1,593 | 79,236 | 22,124 | 23.7 K to 22.1 K (-6.72 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 5.91 | 4,000 | 23,640 | 23,717 | 19.7 K to 23.7 K (+20.29 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 3,652 | 181,650 | 19,717 | 23.4 K to 19.7 K (-15.63 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 13.50 | 6,000 | 81,000 | 23,369 | 17.4 K to 23.4 K (+34.54 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Payment of Exercise | F | 49.74 | 5,486 | 272,874 | 17,369 | 22.9 K to 17.4 K (-24.00 %) |
Dec 20 2013 | VPHM | VIROPHARMA INC | Fletcher Robert C. | V.P., Business Deve ... | Buy | M | 9.99 | 10,012 | 100,020 | 22,855 | 12.8 K to 22.9 K (+77.96 %) |